Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CanSino BiologicsCASBF 69 Forward PE Ratio is 31.34 as of Jul. 14, 2026. GuruFocus rates CASBF with a GF Score™ of 69/100 and a GF Value™ of $8.72 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 409 Drug Manufacturers companies, CanSino Biologics ranks worse than 79.22% on this metric.
CanSino Biologics (OTCPK:CASBF) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
CanSino Biologics Forward PE Ratio Related Terms
CanSino Biologics Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for CanSino Biologics's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CanSino Biologics Forward PE Ratio Chart
CanSino Biologics Annual Data
Trend
2025-12
Forward PE Ratio
58.58
CanSino Biologics Quarterly Data
2025-09
2025-12
Forward PE Ratio
81.48
58.58
CASBF vs ZTS, UTHR: Forward PE Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CanSino Biologics Forward PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where CanSino Biologics's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
CanSino Biologics (CASBF) has a Forward PE Ratio of 31.34 as of Jul. 14, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on CanSino Biologics and its competitors. According to the industry distribution chart, CanSino Biologics ranks #324 out of 409 companies in the Drug Manufacturers industry, placing it in the top 79.2%.
Is CanSino Biologics' Forward PE Ratio too high?
CanSino Biologics' current Forward PE Ratio is 31.34. The Drug Manufacturers industry median Forward PE Ratio is 17.28. CanSino Biologics' value of 31.34 is 81.4% above this industry median. Based on the distribution chart, CanSino Biologics ranks #324 out of 409 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, CanSino Biologics has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CanSino Biologics' Forward PE Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, CanSino Biologics ranks #324 out of 409 companies for Forward PE Ratio. This places CanSino Biologics in the lower half of its industry. The industry median Forward PE Ratio is 17.28. CanSino Biologics' value of 31.34 is 81.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Drug Manufacturers company?
The median Forward PE Ratio among Drug Manufacturers companies is 17.28, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CanSino Biologics's current Forward PE Ratio of 31.34 is 81.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on CanSino Biologics and its competitors. For the Drug Manufacturers industry, the median Forward PE Ratio is 17.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CanSino Biologics's current Forward PE Ratio is 31.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanSino Biologics stock overvalued right now?
Based on GuruFocus' analysis, CanSino Biologics (CASBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $8.72, compared to a current price of $2.60 — trading 70.2% below its estimated fair value. The current Forward PE Ratio is 31.34 and 81.4% above the Drug Manufacturers industry median of 17.28. CanSino Biologics' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For CanSino Biologics (CASBF), the current Forward PE Ratio is 31.34 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CanSino Biologics (CASBF) Overvalued in 2026?
Based on GuruFocus' analysis, CanSino Biologics stock appears to be undervalued.
The current stock price of $2.60 is trading 70.2% below its estimated GF Value™ of $8.72.
GuruFocus considers CanSino Biologics to be Significantly Undervalued.
Key valuation signals for CASBF:
Forward PE Ratio: 31.34
GF Value™: $8.72 vs. price of $2.60 (70.2% below fair value)
Industry Position: 81.4% above the Drug Manufacturers median (#324 of 409)
No single metric tells the full story. See the CASBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CanSino Biologics Inc is engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. The company has a broad portfolio of vaccines and vaccine candidates for several disease areas. Its commercial-stage products are Menhycia and Menphecia, iPneucia, Convidecia and Convidecia Air, and XBB.1.5 Variant, and Ad5-EBOV. The company's clinical-stage products include Tetanus Vaccine, DTcP Infant, Tdcp Adolescent and Adult, Recombinant Poliomyelitis Vaccine, PBPV, and Recombinant Zoster Vaccine, among others. Additionally, it has various vaccine candidates in pre-clinical programs, targeting diseases such as influenza, meningitis, pneumonia, and others. Geographically, the company generates maximum revenue from the People's Republic of China.
69GF Score
Get the complete analysis for CASBF
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CASBF has been successfully added to your 
